C3AR1 and Alzheimer disease: Remarkably, it has been documented that when SB290157 is administered at a concentration of 10 μM, it functions as an agonist for C3aR1 instead of an antagonist [73,74], thus demonstrating the beneficial role of C3aR1 activation in AD.